Restructuring and Asset Impairment Charges (Tables)

12 Months Ended

Mar. 31, 2019

Restructuring and Related Activities [Abstract]

Summary of details for charges recorded

Restructuring charges for the fiscal 2019 initiatives for the year ended March 31, 2019 consisted of the following:

	Year Ended March 31, 2019
(In millions)	U.S. Pharmaceutical and Specialty Solutions		European Pharmaceutical Solutions		Medical-Surgical Solutions		Other		Corporate		Total
Severance and employee-related costs, net	$	50	$	33	$	19	$	16	$	36	$	154
Exit and other-related costs (1)	7		3		20		57		57		144
Asset impairments and accelerated depreciation	6		5		3		18		1		33
Total	$	63	$	41	$	42	$	91	$	94	$	331

(1)    Exit and other-related costs primarily include lease and other contract exit costs associated with closures of facilities and retail pharmacy stores as well as project consulting fees.

The following table summarizes the activity related to the restructuring liabilities associated with the fiscal 2019 initiatives for the year ended March 31, 2019:

(In millions)	U.S. Pharmaceutical and Specialty Solutions			European Pharmaceutical Solutions			Medical-Surgical Solutions			Other			Corporate			Total
Balance, March 31, 2018	$	—		$	—		$	—		$	—		$	—		$	—
Restructuring charges recognized	63			41			42			91			94			331
Non-cash charges	(6		)	(5		)	(3		)	(18		)	(1		)	(33		)
Cash payments	(8		)	(5		)	(23		)	(52		)	(53		)	(141		)
Other	(18		)	7			(1		)	8			(3		)	(7		)
Balance, March 31, 2019 (1)	$	31		$	38		$	15		$	29		$	37		$	150

(1) As of March 31, 2019, the total reserve balance was $150 million of which $117 million was recorded in other accrued liabilities and $33 million was recorded in other noncurrent liabilities.